Clinical Trial Update: Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial update on AVT04 evaluating efficacy, safety, and immunogenicity in moderate-to-severe chronic plaque psoriasis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• AVT04

Snippet

Sponsor: Alvotech Swiss AG | Conditions: Psoriasis | Phase 3 | Status: COMPLETED